FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 375 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Study Explores Jaw Problem Linked to Zoledronic Acid, Finds Risk Factors January 28, 2021 FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung... March 8, 2024 Checking in on our Mental Health May 14, 2021 HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for... September 13, 2023 Load more HOT NEWS Mom Goes From Worried To Mortified After Finding Dark Brown Spot... SABR with Immunotherapy Significantly Improves Event-Free Survival in Patients with Newly... EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a...
